Get the latest news, insights, and market updates on NBY (NovaBay Pharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing standards. As previously disclosed, the NYSE American notified the Company on April 18, 2024 and May 28, 2024 that it was not in compliance with the continued listing standards of the NYSE American Company Guide. Specifically, the notifications indicated that the Company was not i Oct 20, 2025 - $NBY
NovaBay Pharmaceuticals, Inc. (NBY) Declares $0.80 Special Dividend, Boosting Shareholder Value
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. NovaBay Pharmaceuticals, Inc. is one of them. NovaBay Pharmaceuticals, Inc. (NYSE:NBY) is a biopharmaceutical company specializing in anti-infective therapies for inflammation and infection-related conditions. Its flagship product, Avenova, is an antimicrobial lid and lash […] Sep 23, 2025 - $NBY
NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) previously announced a one-time special cash dividend of $0.80 per share for the Company’s common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company’s common stock, NYSE American advi Sep 18, 2025 - $NBY
NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share
EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. “This special dividend reflects our commitmen Aug 26, 2025 - $NBY
NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Investment to support NovaBay’s continued public listing and provide funding for a future strategic transactionEMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company’s non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under Aug 19, 2025 - $NBY
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders
EMERYVILLE, Calif., March 07, 2025--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces it will hold a virtual Special Meeting on April 16, 2025, at which stockholders will vote on a proposal for the liquidation and dissolution of the Company under Delaware law, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Dissolution"). The Special Meeting was announced in a preliminary proxy statement on Schedule 14A filed with the Sec Mar 7, 2025 - $NBY
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal
EMERYVILLE, Calif., January 23, 2025--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC ("PRN") for $11.5 million (the "Asset Sale"). The Asset Sale, representing substantially all of the assets of the Company, was consummated pursuant to the Asset Purchase Agreement dated September 19, 2024, as amended, which NovaBay stockholders Jan 23, 2025 - $NBY
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
EMERYVILLE, Calif., December 19, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that its Reconvened Special Meeting of Stockholders held on December 18, 2024 has been adjourned until January 16, 2025 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold Dec 19, 2024 - $NBY
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple